SCHEMBL23714682

SCHEMBL23714682

Clc1cccc2[nH]c(C3CC3)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.47
GRIA1 P42261 1/20 0.41
CACNG8 Q8WXS5 1/20 0.41
HRH4 Q9H3N8 1/20 0.40
FLT3 P36888 2/20 0.38
CCNT1 O60563 4/20 0.38
CDK9 P50750 4/20 0.38
NOS1 P29475 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2A6 P11509 1/20 0.37
PYGL P06737 1/20 0.36
PYGM P11217 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
YTHDF3 Q7Z739 1/20 0.35
YTHDF1 Q9BYJ9 1/20 0.35
YTHDF2 Q9Y5A9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27751952 0.88 DAO (0.46) DAOGRIA1CACNG8HRH4FLT3
Bromide SCHEMBL7866149 0.85 HRH4 (0.51) HRH4CCNT1CDK9PYGLPYGM
SCHEMBL8554397 0.80 DAO (0.36) DAOGRIA1CACNG8HRH4FLT3
SCHEMBL2156771 0.75 KMT2A (0.48) HRH4FLT3CCNT1CDK9POLB
SCHEMBL15558979 0.75 CUL4A (0.40) GRIA1CACNG8ALDH1A1POLBMAPT
SCHEMBL19643885 0.73 KDM5A (0.47) HRH4CYP1A2ALDH1A1POLBMAPT
SCHEMBL29411876 0.71 GAA (0.53) DAOCYP1A2ALDH1A1POLBMAPT
SCHEMBL7293973 0.71 GAA (0.53) DAOCYP1A2ALDH1A1POLBMAPT
SCHEMBL73543 0.69 AOC3 (0.47) DAOFLT3CYP2A6ALDH1A1MAPT
SCHEMBL27464883 0.69 DAO (0.53) DAOHRH4FLT3NOS1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
CN-115297861-B Compounds and uses thereof 福宏治疗公司 2024-07-12 CN disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
EP-4096667-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
CN-115297861-A Compound and use thereof 福宏治疗公司 2022-11-04 CN disclosed
WO-2021155320-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB DAO 4261/4885GRIA1 3588/4885CACNG8 3087/4885
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB DAO 4261/4885GRIA1 3588/4885CACNG8 3087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.